Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIFJZD)

• Drug Name: AFM11 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell non-hodgkin lymphoma	2B33.5	Phase 1	[1]
leukaemia	2A60-2B33	Phase 1	[2]
Non-hodgkin lymphoma	2B33.5	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMIFJZD

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[7]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[8]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[9]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[10]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[11]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[12]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[13]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[14]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[15]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[16]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[17]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[18]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[19]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[20]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[21]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[22]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Inhibitor	[4]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02848911) Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health.
• [4] A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [11] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [12] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [13] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [14] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [15] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [16] Clinical pipeline report, company report or official report of Genmab.
• [17] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [18] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [19] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [20] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [21] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [22] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [23] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.